Growth Metrics

Sanara MedTech (SMTI) EBITDA (2016 - 2025)

Sanara MedTech (SMTI) has disclosed EBITDA for 15 consecutive years, with $4.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 17.08% year-over-year to $4.9 million, compared with a TTM value of $5.8 million through Sep 2025, up 5.09%, and an annual FY2024 reading of $2.7 million, up 2015.03% over the prior year.
  • EBITDA was $4.9 million for Q3 2025 at Sanara MedTech, up from $2.7 million in the prior quarter.
  • Across five years, EBITDA topped out at $4.9 million in Q3 2025 and bottomed at -$3.3 million in Q4 2021.
  • Average EBITDA over 5 years is -$548938.6, with a median of -$1.1 million recorded in 2021.
  • Peak annual rise in EBITDA hit 1471.29% in 2024, while the deepest fall reached 635.6% in 2024.
  • Year by year, EBITDA stood at -$3.3 million in 2021, then increased by 9.14% to -$3.0 million in 2022, then skyrocketed by 114.88% to $448909.0 in 2023, then crashed by 635.6% to -$2.4 million in 2024, then surged by 304.14% to $4.9 million in 2025.
  • Business Quant data shows EBITDA for SMTI at $4.9 million in Q3 2025, $2.7 million in Q2 2025, and $657969.0 in Q1 2025.